Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2013; 8(2): e57450.
Published online 2013 February 21. doi:  10.1371/journal.pone.0057450
PMCID: PMC3578799

Trypanosoma cruzi Coaxes Cardiac Fibroblasts into Preventing Cardiomyocyte Death by Activating Nerve Growth Factor Receptor TrkA

Partha Mukhopadhyay, Editor



Cardiomyocytes express neurotrophin receptor TrkA that promotes survival following nerve growth factor (NGF) ligation. Whether TrkA also resides in cardiac fibroblasts (CFs) and underlies cardioprotection is unknown.


To test whether CFs express TrkA that conveys paracrine signals to neighbor cardiomyocytes using, as probe, the Chagas disease parasite Trypanosoma cruzi, which expresses a TrkA-binding neurotrophin mimetic, named PDNF. T cruzi targets the heart, causing chronic debilitating cardiomyopathy in ~30% patients.

Methods and Results

Basal levels of TrkA and TrkC in primary CFs are comparable to those in cardiomyocytes. However, in the myocardium, TrkA expression is significantly lower in fibroblasts than myocytes, and vice versa for TrkC. Yet T cruzi recognition of TrkA on fibroblasts, preferentially over cardiomyocytes, triggers a sharp and sustained increase in NGF, including in the heart of infected mice or of mice administered PDNF intravenously, as early as 3-h post-administration. Further, NGF-containing T cruzi- or PDNF-induced fibroblast-conditioned medium averts cardiomyocyte damage by H2O2, in agreement with the previously recognized cardioprotective role of NGF.


TrkA residing in CFs induces an exuberant NGF production in response to T cruzi infection, enabling, in a paracrine fashion, myocytes to resist oxidative stress, a leading Chagas cardiomyopathy trigger. Thus, PDNF-TrkA interaction on CFs may be a mechanism orchestrated by T cruzi to protect its heart habitat, in concert with the long-term (decades) asymptomatic heart parasitism that characterizes Chagas disease. Moreover, as a potent booster of cardioprotective NGF in vivo, PDNF may offer a novel therapeutic opportunity against cardiomyopathies.


Activation of receptor tyrosine kinases TrkA, TrkB and TrkC by the neurotrophins (NTs) nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and NT-3, respectively, is important for proper central nervous system (CNS) development and repair [1], [2]. Conversely, malfunction of Trk receptor signaling in the brain exacerbates Huntington, Alzheimer and other neurodegenerative diseases, a process that can be reversed by NT administration [3], [4].

Trk signaling is also critical for cardiovascular development, as exemplified by mice bearing targeted deletion of NT-3 or TrkC, which exhibit early postnatal mortality and defects in cardiac septation, valvulogenesis, and truncal formation [5], [6]. In adulthood, Trk signaling, particularly the NGF/TrkA axis is critical for maintenance of cardiac nerves [7], [8], [9], and survival of cardiac myocytes [10] and endothelial cells [11]. NGF gene therapy accelerates cardiac repair following myocardial infarction [12] or type 1 diabetes [13], further establishing TrkA as cardioprotective. The known source of NGF that triggers cardiomyocyte survival is the cardiomyocyte itself – hence the dogma that NGF acts on cardiomyocytes through an autocrine input [10], [12]. Whether cardiac fibroblasts (CFs) communicate with cardiomyocytes via NTs to regulate cardiac function and response to stressors remains a mystery, however.

CFs outnumber cardiomyocytes in the adult heart and form a dense network of cells surrounding clusters of myocytes. Thus, fibroblasts are strategically located to influence cardiomyocyte function and response to injury through direct cell-cell interactions and paracrine communication. Although CFs have long been recognized as a major source of cardiac nonbasement membrane extracellular matrix [14], [15], recent evidence indicates that fibroblasts regulate cardiomyocyte phenotype and vice versa, under physiological conditions and in response to injury, through gap junction-based direct cell-cell interaction, and by releasing growth factors and cytokines such as transforming growth factor-β (TGF-β), fibroblast growth factor-2 (FGF-2), interleukin-6 (IL-6) [16], [17], [18]. CFs express receptors for those growth factors and cytokines, several in common with cardiomyocytes and some more abundant in the fibroblasts, like angiotensin receptors, which link the renin-angiotensin-aldosterone system to myocardial and extracellular matrix remodeling and which convey paracrine signals to cardiomyocytes via TGF-β secretion [19]. CFs are the subject of current great excitement as they can be reprogrammed into functional cardiomyocytes using specific transcription factors [20], [21], [22] or micro-RNAs [23], and therefore could be critical for efficient restoration of necrotic cardiomyocytes in cardiomyopathies.

Trypanosoma cruzi causes incurable Chagas disease that afflicts millions of people worldwide, mostly in Latin America. Chagasic patients develop cardiomyopathy, which manifests clinically as arrhythmias, right bundle blocks, apical aneurysms, heart failure and sudden death. Patients may also display gut disturbances that lead to megacolon/megaesophagus. However, detrimental heart and/or gut parasitism occurs in a minority (~30 to 40%) of patients, and even so, only after years or decades of asymptomatic and pathology-free infection [24], [25], raising the possibility that T cruzi orchestrates mutually beneficial protective mechanisms in infected tissues. This hypothesis is reinforced by the fact that, if only 40 to 30% patients develop pathology, then most chagasic patients (60–70%) remain asymptomatic and without detectable cardiac and gut pathology (indeterminate phase) for life.

One mechanism that might explain T cruzi manipulation of tissue survival events results from the trophic actions of parasite-derived neurotrophic factor (PDNF) {Chuenkova, 2011 #2427}. This T cruzi outer membrane protein mimics NTs by interacting with TrkA and TrkC, driving entry into cells of the nervous system while concomitantly activating anti-apoptotic signaling [26], [27], [28], akin to pro-survival actions of endogenous NGF and NT-3 [1], [2]. PDNF, which we originally identified in T cruzi by its neuraminidase activity [29], also transfers sialic acid to β-Gal acceptors (trans-sialidase activity) [30]. However, the Trk-binding activity of PDNF is independent of sialic acid recognition because point mutations in the protein reduce neuraminidase and trans-sialidase activities with no impairment in neurotrophic properties [31] and because the properties of a PDNF-modeled synthetic peptide (21-mer), which reproduces biological activities and signaling of parental PDNF [32]. Moreover, PDNF, after phosphorylation by prosurvival Akt kinase, promotes cell survival in the cell cytosol where sialyl-glycoconjugates are absent [33].

Here we report that CFs express NTs and Trk receptors, and that one of the NT/Trk pairs, NGF/TrkA, plays role in fibroblast-cardiomyocyte communication in response to T cruzi and its PDNF.


Ethics statement

All mouse work was approved by the Institutional Animal Care and Use Committee at Tufts University School of Medicine (Protocol B2010-32) and by the Department of Laboratory Animal Medicine of Tufts University and Tufts Medical Center.

Immunofluorescence – frozen sections

Adult mouse hearts were fixed in 4% paraformaldehyde overnight, dehydrated in 15% and 30% sucrose solutions for 24 hours each, then mounted in OCT solution and sectioned. Sections were permeabilized in 0.1% Triton X-100 for 5 minutes, blocked with PBST/10% FCS overnight at 4°C, then incubated with primary antibody in PBST/5% FCS overnight at 4°C. Secondary antibody was incubated at room temperature for 2 hours. Sections were washed three times with PBST between each step. Images were acquired with Nikon Brightroom Elements software and analyzed by a custom script using NIH Image J software to bin data based on Trk fluorescence levels (Red) and computing mean myosin heavy chain (MHC) and vimentin intensities. Antibodies with concentrations and sources are listed in Table S1.

Immunofluorescence – primary cultures

As above except primary cultures were washed with PBS, fixed in 4% paraformaldehyde for 20 minutes, permeabilized, blocked, and stained. Some cells were stained with 4',6-diamidino-2-phenylindole (DAPI) to visualize nuclei. Images were acquired with SPOT imaging system and prepared in Adobe Photoshop.

Primary cardiomyocyte and cardiac fibroblast isolation

We used a slightly modified version of the procedure described by Sreejit et al [34]. Neonatal C57BL/6 mice (1–3 days old) were sacrificed by decapitation, hearts were dissected and washed twice in PBS, and kept in 20 mM HEPES, 130 mM NaCl, 1 mM NaH2PO4, 4 mM glucose, 3 mM KCl, pH 7.6 for 10 minutes on ice. Hearts were then minced and digested in 0.25% Trypsin-EDTA (Gibco) 3–4 times at 37°C with periodic mixing. Digests were pooled, stopped with DMEM/10% FCS, passed through a 100 µm cell strainer, centrifuged, then plated for 3 hours on 1% gelatin-coated plates in DMEM (Gibco)/F12 Ham's (Sigma) 50[ratio]50, 20% FCS (PAA), 5% horse serum (PAA), 2 mM L-glutamine (Gibco), 0.1 mM nonessential amino acids (Gibco), 3 mM sodium pyruvate (Gibco), and 1 µg/ml bovine insulin (Sigma) with 1x penicillin-streptomycin (Gibco). After three hours, non-adherent cells (cardiomyocytes) were removed and plated onto gelatin-coated plates while adherent cells (cardiac fibroblasts) were grown in DMEM/10% FCS until needed. Purity of preparations was monitored visually and/or by immunofluorescence and was routinely >90%.

In vitro Infection with T cruzi

T cruzi (Tulahuén strain) were harvested from supernatants of infected monolayers of Vero cells where they were maintained. Supernatants were centrifuged at 960 rpm in a tabletop centrifuge to remove any detached cells then parasites were pelleted at 2400 rpm and resuspended in DMEM/0.1% FCS. Parasites were counted in a hemacytometer and added to primary cardiomyocytes or cardiac fibroblasts as well as the H9c2 cardiomyocyte cell line (ATCC). Supernatants of infected cells were cleared by centrifugation, filtered, and frozen or analyzed immediately by ELISA. Monolayers of cells were lysed in Trizol reagent (Invitrogen) for RNA isolation.


Wells of a 96-well plate were coated overnight with NGF capture antibody (Chemicon AB1528, 1[ratio]1000) in coating buffer (50 mM NaHCO3/Na2CO3, pH 9.6, 0.02% NaN3). Wells were blocked in PBST/5% BSA, incubated with supernatants followed by a second NGF antibody (Chemicon AB1526, 1[ratio]1000) then alkaline-phosphatase conjugated detection antibody (Sigma A3687, 1[ratio]1000). All incubations were 90 min at room temperature and wells were washed three times with PBST in between each step. Wells were then incubated with colorigenic AP substrate (Sigma N9389, 1 mg/mL in 100 mM Glycine, 1 mM MgCl2, 1 mM ZnCl2 pH 10.4). NGF concentrations were calculated relative to a standard curve (NGF, Sigma N0513).

Quantitative Reverse-Transcriptase Polymerase Chain Reaction

RNA was isolated from Trizol lysates of cell monolayers according to manufacturer instructions. cDNA was synthesized using Quantitect reverse transcription kit (Qiagen) according to manufacturer instructions. Trk and neurotrophin transcripts were amplified using specific primers and quantified relative to HPRT using SYBR Green (Qiagen). Primer sequences are listed in Table S2.

Neurite extension assay

PC12 rat pheochromocytoma cells (a gift from Dr. Lloyd Greene, Columbia University [35]) were plated on 96-well plates, serum-starved overnight in 0.1% FCS, then incubated with media conditioned by cardiac fibroblasts infected with T cruzi. After 24 hours, cells were fixed in methanol, stained with Diff Quik stain and counted. In parallel, conditioned media from infected CF was pre-incubated with a neutralizing NGF antiserum (Chemicon AB1528, 1[ratio]200) for 30 minutes at room temperature or with normal sheep serum (Chemicon NS114-nc). Neurite bearing (possessing at least one neurite of one cell-body length or greater) cells were quantified by optical microscopy (>200 cells/well).

Lentiviral shRNA knockdown

Lentiviral particles encoding shRNA constructs against TrkA and TrkC were generated in HEK 293 cells and frozen at −80°C until needed in accordance to the instructions of the manufacturer (Open Biosystems). Knockdown conditions were optimized using immunofluorescence to measure Trk expression on the primary cultures of cardiac cells. 40 µL lentiviral particles were added per well of a 24-well plate and cells were cultured for 6 days to allow for expression of constructs.

sPDNF purification

sPDNF was originally cloned from the Silvio X-10/4 strain of T cruzi (GenBank accession number AJ002174), expressed in BL21(DE3) bacteria, and purified by Ni-affinity chromatography, as described previously [36]. sPDNF migrates on SDS-PAGE as a single or double band of MW 68 kDa. If isolated sPDNF contained extra bands, it was re-purified on the same Ni-affinity gels to give rise to homogeneously pure recombinant PDNF. Protein was quantified by scanning densitometry of Coomassie-stained SDS-PAGE gels. sPDNF leter-sterilized (0.22 µ) and kept at 4°C at ~ g/ml PBS (0.01 M phosphate buffered saline, pH 7.2); under these conditions, sPDNF keeps Trk-binding activity for many months.

Mouse experiments

T cruzi infection

T cruzi from supernatants of infected Vero cell monolayers were isolated as described above, washed twice by resuspension in PBS and centrifugation, then counted and diluted in PBS to 1.67×105/mL and kept on ice. 6–8 week old female C57BL/6 mice (Jackson Laboratories) were anesthetized by isoflurane inhalation, then injected with 30 µL T cruzi (5000/mouse) into the left hind footpad. At the indicated timepoints, mice were sacrificed by CO2 asphyxiation and cervical dislocation, a hole was cut in the right atrium, 5 mL PBS was perfused via the left ventricle, and hearts were flash frozen in liquid nitrogen and stored at −80°C or fixed in 4% paraformaldehyde for frozen sections. RNA and DNA were isolated from frozen hearts via Trizol (Invitrogen) extraction according to manufacturer instructions. Parasitemia was evaluated by optical microscopy of blood smears and heart parasite burden was measured by qPCR of a conserved microsatellite DNA sequence in T cruzi according to the procedure of Cummings and Tarleton [37], as previously described [27], [38].

NGF transcript levels were assessed by qPCR of heart cDNA and displayed by the 2−ddCt method using HPRT as an internal control and time-0 as the experimental control. NGF protein levels at day 20 post-infection were assessed by staining frozen sections with NGF antiserum and quantifying signal with ImageJ.

sPDNF in vivo administration

sPDNF was diluted in PBS and injected (200 µl) via tail vein into 6–8 week old female C57BL/6 mice. 25 µg sPDNF was administered at 0, 3, and 24 hrs (2 day timepoint) or 0, 3, 24, 48, 72, and 96 hrs (6 day timepoint). Injection of PBS alone served as a negative control. Mice were perfused with PBS as above and hearts were separated into atria and ventricles and either flash frozen in liquid nitrogen and stored at −80°C or fixed in 4% paraformaldehyde for frozen sections.

Trans-sialidase activity assay

Trans-sialidase activity in tissue lysates was measured by homogenizing tissue at 100 mg/mL in lysis buffer (50 mmol/L Tris-HCl pH 7.2, 0.5 mol/L NaCl, 1% Triton X-100, 1 mmol/L PMSF, 1x protease inhibitor cocktail (Roche)). Enzymatic activity was measured by catalysis of sialic acid from FCS to the 14C-labelled acceptor, N-acetyllactosamine (Sigma) as previously described [36]. Tissue concentrations of sPDNF were calculated from a standard curve obtained by spiking control tissues (where trans-sialidase activity is absent) with known concentrations of sPDNF. Data are composite from two independent experiments.

Cardiomyocyte survival assay

Primary cardiomyocytes were pre-treated with unconditioned (from control cardiac fibroblasts) or conditioned (from T cruzi-infected or sPDNF-administered cardiac fibroblast) media. CoM was centrifuged (2, 000×g, 10 min) and filter-sterilized (0.22 µ) prior to addition to the myocyte cultures. Cardiomyocytes were separately treated with DMEM/0.1% FCS unexposed to cells, with or without 50 ng/mL NGF. In parallel, conditioned media was preincubated with α-NGF serum or control normal serum. Cardiomyocytes were then subjected to 150 µM hydrogen peroxide treatment for 4 hours and stained with Hoechst 33342 and propidium iodide to visualize live/dead cells. Dead cardiomyocytes are seen a pink dots (the result of the merge of dark-red PI and blue Hoechst staining), while viable cardiomyocytes are stained blue by the vital dye Hoechst 33342 and no PI staining. At least 200 cells/well were counted per point.


Statistical tests were performed with GraphPad Prism 5 software using Student's t-test for comparing two values or ANOVA with Tukey or Dunnett's post-test for comparing three or more values. P values are as indicated in figures with p<0.05 considered statistically significant.


In the Myocardium, TrkA is Expressed Preferentially in Cardiomyocytes and TrkC in Cardiac Fibroblasts

Early work by others demonstrated Trk receptors in cardiomyocytes [10], [39], [40]. We used real-time PCR to determine basal levels of Trk receptors in primary cultures of adult and neonatal mouse CFs. We find that fibroblasts express TrkA and TrkC transcripts, TrkA predominating over TrkC, at levels comparable to those in cardiomyocytes (Fig. 1A). Adult and neonatal cardiac cells exhibited similar patterns of Trk expression. Visualization of TrkA and TrkC by immunofluorescence in cardiac fibroblasts is consistent with the mRNA findings (data not shown).

Figure 1
Expression of neurotrophin receptor and ligands in primary cultures of cardiac fibroblasts and myocytes.

In light of this Trk expression we next determined transcript levels of the Trk ligands NGF, BDNF, and NT-3. NGF was most highly expressed in both adult and neonatal cardiac fibroblasts and myocytes, however BDNF transcripts were more prevalent in neonatal cells while NT-3 transcripts increased in adult mice (Fig. 1B). Dissociation curves and agarose gel analysis of qPCR products demonstrated the homogeneity of amplicons (Fig. S1).

To determine TrkA and TrkC protein levels in the myocardium, we reacted heart (ventricle) tissue sections with antibodies against receptors TrkA or TrkC and against markers of CF (vimentin) and cardiomyocytes (myosin heavy chain, MHC), followed by fluorescent-labeled secondary antibodies. Then, we quantified specific fluorescence pixels in the receptors and markers using NIH ImageJ software, revealing TrkA in both myocardial fibroblasts and myocytes but more prominently in the myocytes (Fig. 2A), and TrkC predominating in CFs (Fig. 2B). In validation of this expression pattern, visualization of stained cardiac tissue sections shows that, although TrkA merges with both MHC and vimentin, it prevails with the cardiomyocyte marker (Fig. 2C), quite the contrary of TrkC, which merges primarily with the fibroblast marker vimentin (green) (Fig. 2D).

Figure 2
Cardiomyocytes preferentially expresses TrkA and cardiac fibroblasts TrkC.

T cruzi Infection of Cardiac Fibroblasts, but not Cardiomyocytes, Triggers a Robust Expression of Bioactive NGF

Based on real-time PCR, basal level of NGF transcript in primary neonatal CFs is ~3-fold higher than BDNF and ~120-fold higher than NT-3 transcript (Fig. 1B), analogous to primary cardiomyocyte expression except for NT-3, which is not detectable in the myocytes (Fig. 1B). As T cruzi interacts with both TrkA [26] and TrkC [41], we tested whether NT expression in CFs and/or cardiomyocytes is altered in response to T cruzi infection.

We find that T cruzi-infected CFs, but not cardiomyocytes, exhibit a dramatic increase in NGF expression. For example, NGF transcript in T cruzi-infected CFs increases by more than 9-fold at 24-h post-infection (PI) whereas NGF protein in the culture supernatants is boosted by more than 80-fold at 72-h PI (Fig. 3A). This response is in sharp distinction to the one produced by T cruzi infection of primary cardiomyocytes and of the cardiomyocyte cell line H9c2, which upregulate NGF only slightly and not at all, respectively (Fig, 3A). Early microarray studies showed that T cruzi infection of primary cardiomyocytes upregulate NGF mRNA [42]. Because BDNF and NT-3 transcripts, whether in CFs or myocytes, did not significantly change in response to T cruzi infection (data not shown), they are not studied further here.

Figure 3
T cruzi infection upregulates NGF preferentially in primary cultures of cardiac fibroblasts compared to cardiomyocytes.

Indirect immunofluorescence of cardiac fibroblasts/myocytes co-cultures validates the robust and cell-selective NGF upregulation (Fig. 3B, leftmost panels). Co-staining for NGF, vimentin and MHC confirms the preponderance of NGF in CFs as judged by the preferential merge of fluorescently labeled vimentin with NGF (Fig. 3B).

NGF secreted in response to T cruzi infection is bioactive because 1) conditioned medium (CoM) obtained from T cruzi-infected primary CFs at 72 h post-infection (PI), but not medium from uninfected cells (0-h CoM) strongly promotes neurite outgrowth in PC12 cells (Fig. 3C, left panels) in a time-of-infection dependent manner (Fig. 2C, left bar graph), and 2) an NGF anti-serum blocks the neurite-enhancement effect of active CoM nearly completely (Fig. 3C, right panels and bar graph).

Targeting TrkA in Cardiac Fibroblasts for NGF Upregulation

To determine whether T cruzi exploits fibroblast TrkA or TrkC, or both, to trigger NGF production, CFs were pre-incubated (0.5 h) with antibodies against the neurotrophin receptors prior to T cruzi infection (24 h). If T cruzi uses Trks to increase NGF expression, then neutralizing antibodies against relevant Trks should block the T cruzi action. We find that antibodies against TrkA (α-TrkA) significantly block secretion of NGF (~80% inhibition, P<0.001) while antibodies against TrkC (α-TrkC) are less effective (~36% inhibition, not statistically significant) (Fig. 4A). Further underlying the selectivity of TrkA blockage, antibodies against TrkB (α-TrkB) and against the pan-neurotrophin receptor p75NTR (α-p75NTR), which do not interact with T cruzi [26], [28], exhibit no inhibitory activity. Therefore, these results suggest that T cruzi boosts NGF production in cardiac fibroblasts predominantly through TrkA recognition.

Figure 4
TrkA is targeted by T cruzi for upregulation of NGF in cardiac fibroblasts.

Experiments designed to reduce Trk expression with shRNA validate the conclusion from the antibody blocking experiments. We transfected CFs with lentivirus encoding shRNA constructs for control green fluorescence protein (GFP), TrkA (two distinct vectors), or TrkC (one vector) and infected the transfected cardiac fibroblasts with T cruzi for 24 h. Compared to GFP-transfected fibroblasts, the cell lines transfected with two shTrkA constructs, but not the cell line transfected with the TrkC mRNA silencer, selectively block NGF secretion in response to T cruzi infection (Fig. 4B).

Selective Upregulation of NGF in Cardiac Fibroblasts in Chagasic Hearts

The question, then, is whether T cruzi-induced preferential upregulation of NGF in cultured CFs applies to fibroblasts in their natural myocardium niche.

We infected C57BL/6 mice with T cruzi (Tulahuen strain) and measured the kinetics of parasitemia (by phase-contrast microscopy), heart parasite burden (by qPCR), and cardiac NGF transcript (by qPCR). Parasitemia peaks 11 days PI and heart parasitism 7 days later, a time when parasitemia is no longer detectable (Fig. 5A, left panel). NGF mRNA increases in infected hearts maximally 22–24 d PI, trailing heart parasite burden (Fig. 5A, middle panel), supporting the premise from in vitro experiments that NGF upregulation results from T cruzi recognition of fibroblast-TrkA. Upregulation of NGF transcript is reflected in NGF protein, which increases in infected hearts as quantified with NIH ImageJ software in tissue sections obtained at peak heart parasitism (20-d PI) and stained by indirect immunofluorescence (Fig. 5A, right panel). Visualization of the fluorescence also reveals a sharp NGF upturn in T cruzi-infected hearts (Fig. 4B, leftmost panels). Early studies showed increased NGF in T cruzi-infected hearts [43].

Figure 5
T cruzi infection of the heart upregulate NGF selectively in cardiac fibroblasts.

To determine whether the observed fluorescence is due to antibody recognition of NGF and not to nonspecific staining, we preincubated the NGF antibody with a low concentration of NGF, which eliminates NGF visualization almost completely (Fig. 5B, second panels from the left), establishing the specificity of NGF detection. Co-staining analysis reveals that NGF merges preponderantly with vimentin (yellow) (Fig. 5B, α-NGF/α-vimentin merge panels), confirming the preferential increase in NGF in the CFs of chagasic hearts.

The T cruzi Trk-ligand PDNF Upregulates NGF Preferentially in Cardiac Fibroblasts In Vitro and in the Heart Following Intravenous Administration

Given that T cruzi upregulates NGF in cardiac fibroblasts through TrkA, which in turn is recognized by T cruzi via PDNF [26], then PDNF must be the T cruzi ligand mediating the NGF-stimulatory effect. This prediction was tested in CFs and myocytes in culture and in the myocardium.

PDNF consists of a N-terminal region, containing the catalytic [44] [44] and Trk-binding [26], [27], [28], [31] sites, and a C-terminal long terminal repeat [45], [46], originally identified as shed acute phase antigen (SAPA) [47]. Here we used a short-form of PDNF (sPDNF), devoid of SAPA, recombinantly expressed in bacteria as a soluble protein [31] that retains TrkA/TrkC binding [27], [28].

We find that, in fibroblasts, sPDNF stimulates NGF transcript (Fig. 5, left panel) and protein (Fig. 5, middle panel) quickly (3-h post-injection) and dose-dependently. Like T cruzi, sPDNF is ineffective in upregulating NGF in primary cardiomyocytes (Fig. 6, left and right panels). Furthermore, and in concert with the use of TrkA by T cruzi to enhance NGF production (Fig. 4), the TrkA autophosphorylation inhibitor K252a completely reverses the NGF stimulatory effect of sPDNF, as does the TrkA downstream (Mek1/2 kinases) signaling inhibitor U0126 (Fig. 6, right panel). This indicates that sPDNF requires TrkA signaling to increase NGF production in CFs.

Figure 6
The T cruzi Trk-ligand sPDNF preferentially upregulates NGF in cardiac fibroblasts requiring TrkA signaling.

Prior to addressing whether sPDNF augments NGF expression in vivo, we obtained preliminary pharmacokinetics parameters by measuring sPDNF decay in the blood and myocardium following intravenous (iv) administration. Tissue sPDNF was quantified by its intrinsic trans-sialidase activity (absent in mammalian tissues) using a 14C-based assay [48]. sPDNF has a half-life of ~15 min in the blood, gains access to the atria and ventricle maximally at least 15 min post-administration, and remains in the heart for >30 min (Fig. S2A). Assuming negligible loss of trans-sialidase activity in tissues after iv injection, the amount of sPDNF uptake by the heart after a single dose is very small, or ~1/500th the amount of injected sPDNF (Fig. S2B).

Yet, despite low levels in cardiac tissues, a single iv dose (8.3 mg/Kg) of sPDNF ups cardiac NGF mRNA as early as 3-h post-injection (Fig. S3). Daily iv injections of a lower sPDNF dose (1.4 mg/Kg) for 2 or 6 days also increases cardiac NGF transcript (Fig. 7A) and protein (Fig. 7B). As in chagasic hearts, NGF increases selectively in CFs following iv sPDNF, as indicated by the merge of NGF, stained red, with vimentin, stained green, giving rise to yellow-merged color (Fig. 7C, α-NGF/α-vimentin merge panels). Fluorescently labeled NGF does not appear to merge with the cardiomyocyte marker MHC (Fig. 7, α-NGF/α-MHC merge panels). To confirm immunofluorescence results, we measured NGF protein by ELISA in heart extracts following i.v. sPDNF and found increased levels as early as two hours post-injection (Fig. S4). These findings indicate that T cruzi upregulates NGF in vitro and in vivo through PDNF.

Figure 7
Intravenous administration of PDNF upregulates nerve growth factor in the heart selectively on cardiac fibroblasts.

Conditioned Media Obtained from T cruzi-Infected or sPDNF-Stimulated Cardiac Fibroblasts Confer Cardiomyocyte Protection against Oxidative Stress

We used conditioned medium (CoM) and un-conditioned medium (Un-CoM), obtained from primary cultures of infected with T cruzi (24 h) or not, respectively, to determine if the T cruzi-CF interaction triggers cardiomyocyte survival via paracrine signaling. CoM and Un-CoM were centrifuged (2, 000×g, 10 min) and filtered through 0.22 µ pores prior to use. Then, we assessed the protective effect of CoM in cardiomyocytes exposed to cardiotoxic H2O2 using the propidium iodide and vital stain Hoechst 33342 procedure.

Compared to un-CoM and medium, CoM significantly (P<0.001) reverses the death-causing effect of H2O2 (Fig. 8A, scatter plot). Exogenous NGF (50 ng/ml) also protects cardiomyocytes against H2O2 in this assay (Fig. 8A; compare medium with medium + NGF). Furthermore, a neutralizing NGF serum (α-NGF) significantly (P<0.001) inhibits the protective action of CoM under conditions control normal serum (NSS) does not (Fig. 8A, scatter plot). This indicates that NGF is at least one of the cardioprotective factors that T cruzi induces cardiac fibroblasts to secrete into the extracellular milieu (i.e., CoM). The panel on the right of Fig. 8A displays representative staining of each of these conditions.

Figure 8
Conditioned media from T cruzi-infected or sPDNF-stimulated cardiac fibroblasts protect cardiomyocytes against oxidative stress.

Fitting perfectly well with the concept that T cruzi, via PDNF, augments NGF secretion in CFs, CoM produced by stimulating CFs at low sPDNF concentration and for a short time (50 ng/ml, 3 h) significantly protects cardiomyocytes against H2O2-induced cell death, a protection abrogated by a neutralizing NGF antiserum (Fig. 8B).


Our results demonstrate, for the first time, that primary neonatal CFs express transcripts of NGF/TrkA and NT-3/TrkC pairs, and of BDNF, a pattern similar to that of primary cardiomyocytes except for the very low/undetectable expression of NT-3 in the myocytes (Figs. 1A and B). NGF had the highest expression of the three in both adult and neonatal cardiac cells, whereas BDNF expression declined and NT-3 expression increased from neonatal to adult cells.

NGF is the most studied NT in cardiac injury. Earlier findings showed that NGF, which signals via TrkA but not TrkB and TrkC [2], triggers prosurvival activity in primary cardiomyocytes through an autocrine mechanism [10]. This activity may be beneficial in vivo, as NGF gene therapy is cardioprotective in models of myocardial infarction [12] and diabetes [13]. However, those in vivo studies were not designed not tell whether myocardial NGF secreted under physiological conditions and/or in response to stressors arise from cardiomycytes. Furthermore, although it has been established that cardiac injury, such as in hypoxemia/reperfusion or myocardial infarction, sharply augments cardiac NGF [7], [12], [13], nothing is known of the ligands and cell-surface recepor(s) that trigger NGF upregulation, except for endothelin-1, which regulates NGF expression in cardiomycytes [8]. However, it remains unknown whether endothelin-1 alters cardiac NGF expression in fibroblasts, which express endothelin-1 receptors [49]. Identification of the molecules that control NGF upregulation is clearly important to better understand cardiac function, response to injury, and design therapeutics to boost myocardial NGF, including by systemic administration.

T cruzi invades the heart where it causes acute myocarditis that lasts a few months, followed by a chronic debilitating cardiomyopathy in ~30% infected individuals many years after the infection [24], [25]. Therefore, the possibility exists that T cruzi/host interaction triggers reactions that reduce or prevent damage of infected tissues. This idea is backed up by our findings presented here, which demonstrate that T cruzi triggers an exuberant production of cardioprotective NGF (more than 80-fold increase) in cardiac cells growing in culture, predominantly in fibroblasts (Fig. 3). This NGF boost response discriminates between T cruzi recognition of TrkA and TrkC, as it requires the former but not the latter (Fig. 4), an in vitro response analogous to that seen in chagasic hearts (Fig. 5). Reflecting the T cruzi recognition of Trks via its PDNF, bacterially expressed PDNF (sPDNF) reproduces the effect of T cruzi infection, for it selectively boosts NGF in fibroblasts outside (Fig. 6) and inside their natural myocardial niche (Fig. 7).

Given the prosurvival action of NGF on cardiomyocytes and the vigorous upregulation of bioactive NGF selectively in fibroblasts in response to T cruzi infection or sPDNF stimulation, it is reasonable to hypothesize that T cruzi-cardiac fibroblast interaction protects cardiomyocytes via a NGF-dependent paracrine mechanism. This prediction proved to be correct as medium conditioned by T cruzi infection or sPDNF stimulation of fibroblasts prevented cardiomyocyte death resulting from oxidative stress (hydrogen peroxide) (Fig. 8). It has long been known that oxidative stress kills cardiomyocytes [50], including in chagasic cardiomyopathy development [51].

Furthermore, NGF released following T cruzi-fibroblast interaction may also protect cardiomyocytes against deleterious effects additional to the oxidative stress shown here, as judged by the findings of others demonstrating NGF protection of cardiomyocytes subjected to growth factor deprivation, hypoxia/reoxygenation, and angiotensin II stimulation [12]. We therefore hypothesize that enhanced NGF secretion following T cruzi-PDNF recognition of fibroblast-TrkA is a mechanism responsible for long term symtomless and relatively pathology-free T cruzi homing in the heart.

It will be of importance to know the biological outcome of T cruzi binding to TrkA or TrkC on cardiomyocytes, and TrkC on fibroblasts. It will also be important to know whether endogenous TrkA-binding molecules such as NGF reproduce the T cruzi action in fibroblasts.

Finally, as PDNF binding to TrkA on fibroblasts releases NGF (Fig. 6) which, in turn, protects cardiomyocytes against oxidative stress (Fig. 8B) and perhaps other insults [10], and, as intravenous administration of sPDNF boosts cardiac NGF (Fig. 7), our results offer a possible novel translational medicine opportunity for cardiomyopathies where NGF gene therapy has proven to be valuable in myocardial infarction [12] and diabetes [52]. PDNF administration might also be useful in preventing or slowing down cardiomyocyte degeneration. PDNF might be a better therapeutic than NGF because it 1) activates both prosurvival TrkA and TrkC while NGF activates only TrkA; 2) has a unique dual prosurvival activity by directly activating TrkA and TrkC outside cells and, in the intracellular milieu, pro-survival Akt kinase [33]; 3) creates a positive TrkA signaling loop by robustly upregulating NGF; 4) has a relatively long half-life (detectable in the heart for >30 min after iv injection, see Fig. S2).

Supporting Information

Figure S1

sPDNF pharmacokinetics in the heart following intravenous administration. A) Dissociation curves of qPCR reactions using SYBR green detector. Two samples each of adult cardiac fibroblast and cardiomyocyte cDNA were probed for the indicated genes and dissociation curves are displayed. B) qPCR products for HPRT, Trk receptors, and NTs were run on an ethidium-bromide stained 1.5% agarose gel to demonstrate homogeneity of reactions. Bottom two bands of ladder are 100 and 200 base pairs (bp) for comparison and expected product sizes for each amplicon are listed below gel.


Figure S2

sPDNF pharmacokinetics in the heart following intravenous administration. sPDNF was injected at 1.4 mg/kg (or 25 µg per mouse) into female C57BL/6 mice (5/group), and the mice sacrificed at 15, 30 and 120 min post-injection, perfused with PBS (5 ml), and sPDNF assessed in homogenized atria and ventricles by measuring trans-sialidase activity of the cardiac tissues by a C14-based assay. A) Decay of concentration of sPDNF in tissues as ng/mg tissues; B) decay of sPDNF in tissues as % injected sPDNF.


Figure S3

Intravenous administration of sPDNF increases NGF protein by ELISA. Tissue extracts from pharmacokinetics experiment (Fig. S2) were tested for NGF concentration by ELISA. Two technical replicates each on duplicate points are graphed as mean + s.d., * P<0.05.


Figure S4

Intravenous administration of sPDNF ups NGF mRNA as early as three hours post-injection. C57BL/6 mice (two per point) were injected with 150 µg sPDNF or PBS vehicle medium into their tail veins. After 3, 6, 9, or 12 hours, mice were sacrificed via CO2 asphyxiation, and their cardiac NGF transcript quantified by qPCR. Fold expression was calculated using the 2−ddCt method using HPRT as the internal control and PBS-injected mice as the negative control.


Table S1

Antibodies and concentrations. Antibody sources and concentrations used in immunofluorescence assays.


Table S2

qPCR Primers. Sequences of primers used for qPCR reactions.


Funding Statement

This work was supported by NIH grants NS40574 and NS42960. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Skaper S (20012) The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol 846: 1–12 [PubMed]
2. Huang EJ, Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609–642 [PubMed]
3. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90: 905–981 [PubMed]
4. Barcelos LS, Duplaa C, Krankel N, Graiani G, Invernici G, et al. (2009) Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res 104: 1095–1102 [PMC free article] [PubMed]
5. Donovan MJ, Hahn R, Tessarollo L, Hempstead BL (1996) Identification of an essential nonneuronal function of neurotrophin 3 in mammalian cardiac development. Nat Genet 14: 210–213 [PubMed]
6. Tessarollo L, Tsoulfas P, Donovan MJ, Palko ME, Blair-Flynn J, et al. (1997) Targeted deletion of all isoforms of the trkC gene suggests the use of alternate receptors by its ligand neurotrophin-3 in neuronal development and implicates trkC in normal cardiogenesis. Proc Natl Acad Sci U S A 94: 14776–14781 [PubMed]
7. Zhou S, Chen LS, Miyauchi Y, Miyauchi M, Kar S, et al. (2004) Mechanisms of cardiac nerve sprouting after myocardial infarction in dogs. Circ Res 95: 76–83 [PubMed]
8. Ieda M, Fukuda K, Hisaka Y, Kimura K, Kawaguchi H, et al. (2004) Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. J Clin Invest 113: 876–884 [PMC free article] [PubMed]
9. Ieda M, Kanazawa H, Ieda Y, Kimura K, Matsumura K, et al. (2006) Nerve growth factor is critical for cardiac sensory innervation and rescues neuropathy in diabetic hearts. Circulation 114: 2351–2363 [PubMed]
10. Caporali A, Sala-Newby GB, Meloni M, Graiani G, Pani E, et al. (2008) Identification of the prosurvival activity of nerve growth factor on cardiac myocytes. Cell Death Differ 15: 299–311 [PMC free article] [PubMed]
11. Cantarella G, Lempereur L, Presta M, Ribatti D, Lombardo G, et al. (2002) Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J 16: 1307–1309 [PubMed]
12. Meloni M, Caporali A, Graiani G, Lagrasta C, Katare R, et al. (2010) Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res 106: 1275–1284 [PMC free article] [PubMed]
13. Meloni M, Descamps B, Caporali A, Zentilin L, Floris I, et al. (2012) Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Diabetes 61: 229–240 [PMC free article] [PubMed]
14. Bashey RI, Donnelly M, Insinga F, Jimenez SA (1992) Growth properties and biochemical characterization of collagens synthesized by adult rat heart fibroblasts in culture. J Mol Cell Cardiol 24: 691–700 [PubMed]
15. Eghbali M, Blumenfeld OO, Seifter S, Buttrick PM, Leinwand LA, et al. (1989) Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization. J Mol Cell Cardiol 21: 103–113 [PubMed]
16. Souders CA, Bowers SL, Baudino TA (2009) Cardiac fibroblast: the renaissance cell. Circ Res 105: 1164–1176 [PMC free article] [PubMed]
17. Ottaviano FG, Yee KO (2011) Communication signals between cardiac fibroblasts and cardiac myocytes. J Cardiovasc Pharmacol 57: 513–521 [PubMed]
18. Kakkar R, Lee RT (2010) Intramyocardial fibroblast myocyte communication. Circ Res 106: 47–57 [PMC free article] [PubMed]
19. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS (1998) Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 40: 352–363 [PubMed]
20. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, et al. (2010) Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142: 375–386 [PMC free article] [PubMed]
21. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, et al. (2012) In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485: 593–598 [PMC free article] [PubMed]
22. Song K, Nam YJ, Luo X, Qi X, Tan W, et al. (2012) Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485: 599–604 [PMC free article] [PubMed]
23. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, et al. (2012) MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 110: 1465–1473 [PMC free article] [PubMed]
24. Tanowitz HB, Machado FS, Jelicks LA, Shirani J, de Carvalho AC, et al. (2009) Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog Cardiovasc Dis 51: 524–539 [PMC free article] [PubMed]
25. Rassi A Jr, Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375: 1388–1402 [PubMed]
26. Chuenkova MV, PereiraPerrin M (2004) Chagas' disease parasite promotes neuron survival and differentiation through TrkA nerve growth factor receptor. J Neurochem 91: 385–394 [PubMed]
27. de Melo-Jorge M, PereiraPerrin M (2007) The Chagas' disease parasite Trypanosoma cruzi exploits nerve growth factor receptor TrkA to infect mammalian hosts. Cell Host Microbe 1: 251–261 [PubMed]
28. Weinkauf C, PereiraPerrin M (2009) Trypanosoma cruzi promotes neuronal and glial cell survival through the neurotrophic receptor TrkC. Infect Immun 77: 1368–1375 [PMC free article] [PubMed]
29. Pereira ME (1983) A developmentally regulated neuraminidase activity in Trypanosoma cruzi. Science 219: 1444–1446 [PubMed]
30. Schenkman S, Pontes de Carvalho L, Nussenzweig V (1992) Trypanosoma cruzi trans-sialidase and neuraminidase activities can be mediated by the same enzymes. J Exp Med 175: 567–575 [PMC free article] [PubMed]
31. Chuenkova MV, Pereira MA (2000) A trypanosomal protein synergizes with the cytokines ciliary neurotrophic factor and leukemia inhibitory factor to prevent apoptosis of neuronal cells. Mol Biol Cell 11: 1487–1498 [PMC free article] [PubMed]
32. Chuenkova MV, PereiraPerrin M (2005) A synthetic peptide modeled on PDNF, Chagas' disease parasite neurotrophic factor, promotes survival and differentiation of neuronal cells through TrkA receptor. Biochemistry 44: 15685–15694 [PubMed]
33. Chuenkova MV, PereiraPerrin M (2009) Trypanosoma cruzi targets Akt in host cells as an intracellular antiapoptotic strategy. Sci Signal 2: ra74. [PMC free article] [PubMed]
34. Sreejit P, Kumar S, Verma RS (2008) An improved protocol for primary culture of cardiomyocyte from neonatal mice. In Vitro Cell Dev Biol Anim 44: 45–50 [PubMed]
35. Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 73: 2424–2428 [PubMed]
36. Chuenkova M, Pereira M, Taylor G (1999) trans-sialidase of Trypanosoma cruzi: location of galactose-binding site(s). Biochem Biophys Res Commun 262: 549–556 [PubMed]
37. Cummings KL, Tarleton RL (2003) Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol 129: 53–59 [PubMed]
38. Caradonna K, PereiraPerrin M (2009) Preferential brain homing following intranasal administration of Trypanosoma cruzi. Infect Immun 77: 1349–1356 [PMC free article] [PubMed]
39. Cai D, Holm JM, Duignan IJ, Zheng J, Xaymardan M, et al. (2006) BDNF-mediated enhancement of inflammation and injury in the aging heart. Physiol Genomics 24: 191–197 [PubMed]
40. Kawaguchi-Manabe H, Ieda M, Kimura K, Manabe T, Miyatake S, et al. (2007) A novel cardiac hypertrophic factor, neurotrophin-3, is paradoxically downregulated in cardiac hypertrophy. Life Sci 81: 385–392 [PubMed]
41. Weinkauf C, PereiraPerrin M (2009) Trypanosoma cruzi Promotes Neuronal and Glial Cell Survival through the Neurotrophic Receptor TrkC. Infect Immun 77: 1368–1375 [PMC free article] [PubMed]
42. Manque PA, Probst CM, Pereira MC, Rampazzo RC, Ozaki LS, et al. (2011) Trypanosoma cruzi infection induces a global host cell response in cardiomyocytes. Infect Immun 79: 1855–1862 [PMC free article] [PubMed]
43. Martinelli PM, Camargos ER, Azevedo AA, Chiari E, Morel G, et al. (2006) Cardiac NGF and GDNF expression during Trypanosoma cruzi infection in rats. Auton Neurosci 130: 32–40 [PubMed]
44. Buschiazzo A, Amaya MF, Cremona ML, Frasch AC, Alzari PM (2002) The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol Cell 10: 757–768 [PubMed]
45. Schenkman S, Eichinger D, Pereira ME, Nussenzweig V (1994) Structural and functional properties of Trypanosoma trans-sialidase. Annu Rev Microbiol 48: 499–523 [PubMed]
46. Pereira ME, Mejia JS, Ortega-Barria E, Matzilevich D, Prioli RP (1991) The Trypanosoma cruzi neuraminidase contains sequences similar to bacterial neuraminidases, YWTD repeats of the low density lipoprotein receptor, and type III modules of fibronectin. J Exp Med 174: 179–191 [PMC free article] [PubMed]
47. Affranchino JL, Ibanez CF, Luquetti AO, Rassi A, Reyes MB, et al. (1989) Identification of a Trypanosoma cruzi antigen that is shed during the acute phase of Chagas' disease. Mol Biochem Parasitol 34: 221–228 [PubMed]
48. Scudder P, Doom JP, Chuenkova M, Manger ID, Pereira ME (1993) Enzymatic characterization of beta-D-galactoside alpha 2,3-trans-sialidase from Trypanosoma cruzi. J Biol Chem 268: 9886–9891 [PubMed]
49. Katwa LC, Guarda E, Weber KT (1993) Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 27: 2125–2129 [PubMed]
50. Crow MT, Mani K, Nam YJ, Kitsis RN (2004) The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 95: 957–970 [PubMed]
51. Wen JJ, Vyatkina G, Garg N (2004) Oxidative damage during chagasic cardiomyopathy development: role of mitochondrial oxidant release and inefficient antioxidant defense. Free Radic Biol Med 37: 1821–1833 [PubMed]
52. Kane NM, Howard L, Descamps B, Meloni M, McClure J, et al. (2012) Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells 30: 643–654 [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science